1. Introduction {#j_med-2018-0026_s_001}
===============

Colorectal cancer(CRC) is one of the most diagnosed malignant carcinoma in the digestive system \[[@j_med-2018-0026_ref_001]\]. In the United States, it was the 4^th^ most diagnosed cancer with an estimate of more than 140,000 new cases and 50,000 deaths in year 2012 \[[@j_med-2018-0026_ref_002]\]. However, the mortality from colorectal cancer has decreased by about 35% in recent decades attributing the success to effective colorectal screening methods and treatment modalities. The occurrence and development of colorectal cancer is accompanied by a series of molecular biological changes. The ideal tumor marker for screening colorectal cancer should have high sensitivity and specificity with easy management.

CA72-4 is a glycoprotein found on the surface of many malignant carcinoma cells \[[@j_med-2018-0026_ref_003]\], including colorectal cancer, ovarian cancer \[[@j_med-2018-0026_ref_004]\], gastric cancer \[[@j_med-2018-0026_ref_005]\] and pancreatic cancer. Several published studies have evaluated the diagnostic performance of serum CA72-4 as biomarker for colorectal cancer diagnosis. In our present study, we included the previously published relevant studies about CA72-4 as a biomarker for colorectal diagnosis and pooled the data in order to further evaluate its clinical value.

2. Materials and methods {#j_med-2018-0026_s_002}
========================

2.1. Publication identification {#j_med-2018-0026_s_002_s_001}
-------------------------------

In order to identify all the relevant studies, the electronic databases of Pubmed, Medline, Web of Science, Cochrane Embase, CBMand CNKI were systematically searched by two reviewers (Han Yanqing, Dong Cheng) independently. The publication searching terms were as follows: "colorectal cancer", "colorectal carcinoma", "colon cancer", "rectal cancer", "CA72-4", "CA724", "Tumor-associated glycoprotein 72 (TAG-72)". The references of included studies were also screened to identify potential suitable publications.

2.2. Study inclusion and exclusion criteria {#j_med-2018-0026_s_002_s_002}
-------------------------------------------

Inclusion criteria: (1) The patients were diagnosed with colorectal cancer with pathology conformation; (2)Serum level of CA72-4 was extracted from the original publications; (3)Enough data such as tpfpfn and tnwas extracted from the included studies to calculate the diagnostic sensitivity and specificity; (4) The language was limited to English and Chinese; Exclusion criteria: (1) Studies without enough data or cases, and use of abstract publications; (2) Colorectal cancer patients were not confirmed by pathology examination; (3) Duplicated publications or data; (4) Papers published in other languages other than English or Chinese.

2.3. Quality assessment of the included studies {#j_med-2018-0026_s_002_s_003}
-----------------------------------------------

The general methodological qualities of the 22 included publications were assessed by two reviewers (Dong Cheng and Xu Ling) independently through an eleven items questionnaire provided by Cochrane Reviews Handbook.

2.4. Statistical method {#j_med-2018-0026_s_002_s_004}
-----------------------

The statistical heterogeneity among the 22 included publications was evaluated by I^2^ test. If I^2^\>50%, the data was pooled by Dersimonian-Laird method (random effect model). Otherwise, the data was calculated by fixed-effect methods. The diagnostic performance of serum CA72-4 as a biomarker in the diagnosis of colorectal cancer was evaluated by sensitivity and specificity. \[sensitivity=true positive/(true positive+ false negative), specificity=true negative/( true negative+ false positive)\]. All the data was analyzed by MetaDiSc 1.4 and Stata/SE 11.0 statistical software.

3. Results {#j_med-2018-0026_s_003}
==========

3.1. Main character of the included studies {#j_med-2018-0026_s_003_s_001}
-------------------------------------------

A total of 22 studies \[[@j_med-2018-0026_ref_006],[@j_med-2018-0026_ref_007],[@j_med-2018-0026_ref_008],[@j_med-2018-0026_ref_009],[@j_med-2018-0026_ref_010],[@j_med-2018-0026_ref_011],[@j_med-2018-0026_ref_012],[@j_med-2018-0026_ref_013],[@j_med-2018-0026_ref_014],[@j_med-2018-0026_ref_015],[@j_med-2018-0026_ref_016],[@j_med-2018-0026_ref_017],[@j_med-2018-0026_ref_018],[@j_med-2018-0026_ref_019],[@j_med-2018-0026_ref_020],[@j_med-2018-0026_ref_021],[@j_med-2018-0026_ref_022],[@j_med-2018-0026_ref_023],[@j_med-2018-0026_ref_024],[@j_med-2018-0026_ref_025],[@j_med-2018-0026_ref_026],[@j_med-2018-0026_ref_027]\] with 2474 colorectal patients and 1576 controls were includedwith meta-analysis. Initially, 872 studies were identified through the electronic databases search. After reviewing the title, abstract and full text, 22 publications were finally included according to the study inclusion and exclusion criteria ([Figure 1](#j_med-2018-0026_fig_001){ref-type="fig"}). The main character of the included 22 original studies is demonstrated by [Table 1](#j_med-2018-0026_tab_001){ref-type="table"}.

![The publication searching flow chart](med-13-164-g001){#j_med-2018-0026_fig_001}

###### 

The main character of the included 22 publications

  Author           Year   tP    fp   fn    tn    Sensitivity        Specificity
  ---------------- ------ ----- ---- ----- ----- ------------------ ------------------
  Fiorella         1993   86    2    114   98    0.43 (0.36-0.50)   0.98 (0.93-1.00)
  Sun Wei          2000   21    2    37    27    0.36 (0.24-0.50)   0.93 (0.77-0.99)
  He Hui           2004   20    2    36    28    0.36 (0.23-0.50)   0.93 (0.78-0.99)
  Yue Lin          2006   30    3    57    57    0.34 (0.25-0.45)   0.95 (0.86-0.99)
  Zhu Zili         2006   45    15   22    63    0.67 (0.55-0.78)   0.81 (0.70-0.89)
  Liu Shengli      2007   34    2    57    33    0.37 (0.27-0.48)   0.94 (0.81-0.99
  QiuBing          2008   14    2    24    28    0.37 (0.22-0.54)   0.93 (0.78-0.99)
  Dai Peng         2008   55    14   85    19    0.39 (0.31-0.48)   0.58 (0.39-0.75)
  Pan Aiping       2009   56    13   29    65    0.66 (0.55-0.78)   0.83 (0.73-0.91)
  Jiang Xiaoting   2010   62    20   99    80    0.39 (0.31-0.46)   0.80 (0.71-0.87)
  Huang Fujiao     2011   14    3    27    43    0.34 (0.20-0.51)   0.93 (0.82-0.99)
  Wan Caifeng      2011   68    10   34    40    0.67 (0.57-0.76)   0.80 (0.66-0.90)
  Yao Aiping       2011   73    10   117   40    0.38 (0.31-0.46)   0.80 (0.66-0.90)
  Hu Xiaoai        2011   14    3    27    43    0.34 (0.20-0.51)   0.93 (0.82-0.99)
  Chen Jun         2012   292   7    62    46    0.82 (0.78-0.86)   0.87 (0.75-0.95)
  Wang Xiuyin      2012   64    34   48    182   0.57 (0.47-0.66)   0.84 (0.79-0.89)
  Song Peidong     2012   10    1    40    29    0.20 (0.10-0.34)   0.97 (0.83-1.00)
  TianHua          2013   35    27   25    93    0.58 (0.45-0.71)   0.78 (0.69-0.85)
  Zhu Xiaofei      2013   141   18   104   128   0.58 (0.51-0.64)   0.88 (0.81-0.93)
  GuoQinhua        2013   15    1    61    97    0.20 (0.11-0.30)   0.99 (0.94-1.00)
  LvZhongchuan     2013   63    21   97    79    0.39 (0.32-0.47)   0.79 (0.70-0.87)
  Cheng Jinling    2017   15    9    45    39    0.25 (0.15-0.38)   0.81 (0.67-0.91)

3.2. Methodological qualities of the included studies {#j_med-2018-0026_s_003_s_002}
-----------------------------------------------------

The methodological quality of the included 22 publications was evaluated by an 11 items questionnaire ([Figure 2](#j_med-2018-0026_fig_002){ref-type="fig"}) and indicates the general quality was poor.

![The methodological quality summary for each included study. (The authors'judgments for each risk of bias item. + is "low risk"; - is "high risk''; ?is"moderate risk").](med-13-164-g002){#j_med-2018-0026_fig_002}

3.3. Combined sensitivity for serum CA72-4 in diagnosis of colorectal cancer {#j_med-2018-0026_s_003_s_003}
----------------------------------------------------------------------------

Due to statistical heterogeneity across the 22 studies (I^2^=93.7%), the data was pooled by Dersimonian-Laird method. The combined diagnostic sensitivity was 0.50 (95%CI:0.48-0.52) for serum CA72-4 as a biomarker in the diagnosis of colorectal cancer, [Figure 3](#j_med-2018-0026_fig_003){ref-type="fig"}.

![The diagnostic sensitivity of serum CA72-4 in the diagnosis of colorectal cancer](med-13-164-g003){#j_med-2018-0026_fig_003}

3.4. Combined specificity for serum CA72-4 in diagnosis of colorectal cancer {#j_med-2018-0026_s_003_s_004}
----------------------------------------------------------------------------

The diagnostic specificity was pooled by random effect model because of statistical heterogeneity (I^2^=78.2%). The pooled specificity was 0.86 (95%CI:0.84-0.88) for serum CA72-4 as a biomarker in the diagnosis of colorectal cancer, [Figure 4](#j_med-2018-0026_fig_004){ref-type="fig"}.

![The diagnostic specificity of serum CA72-4 in the diagnosis of colorectal cancer](med-13-164-g004){#j_med-2018-0026_fig_004}

3.5. Combined positive likelihoodratio (Positive LR) {#j_med-2018-0026_s_003_s_005}
----------------------------------------------------

The data was pooled through random effect model because of significant statistical heterogeneity among the 22 publications (I^2^=73.1%). The combined Positive LR was 3.41 (95%CI:2.57-4.53), [Figure 5](#j_med-2018-0026_fig_005){ref-type="fig"}.

![Combined positive likelihoodratio(Positive LR) for serum CA72-4 in the diagnosis of colorectal cancer](med-13-164-g005){#j_med-2018-0026_fig_005}

3.6. Combined negative likelihoodratio (negative LR) {#j_med-2018-0026_s_003_s_006}
----------------------------------------------------

The negative LR was pooled by random effect model for significant statistical heterogeneity across the publications (I^2^=89.5%). The combined negative LR was 0.62 (0.55-0.71), [Figure 6](#j_med-2018-0026_fig_006){ref-type="fig"}.

![Combined negative likelihoodratio(negative LR) for serum CA72-4 in the diagnosis of colorectal cancer](med-13-164-g006){#j_med-2018-0026_fig_006}

3.7. Combined diagnosed odds ratio(DOR) {#j_med-2018-0026_s_003_s_007}
---------------------------------------

The diagnostic odds ratio (DOR) for serum CA72-4 as a biomarker in the diagnosis of colorectal cancer was pooled by random effects model. The pooled DOR was 6.18 with the 95%CI of 4.17-9.17, [Figure 7](#j_med-2018-0026_fig_007){ref-type="fig"}.

![Combined DOR for serum CA72-4 in the diagnosis of colorectal cancer](med-13-164-g007){#j_med-2018-0026_fig_007}

3.8. The diagnostic HSROC of serum CA72-4 in the diagnosis of colorectal cancer {#j_med-2018-0026_s_003_s_008}
-------------------------------------------------------------------------------

The pooled HSROC curve was calculated by sensitivity against (1-specificity). The pooled area under the ROC curve (AUC) was 0.73 for serum CA72-4 in the diagnosis of colorectal cancer, [Figure 8](#j_med-2018-0026_fig_008){ref-type="fig"}.

![The pooled HSROC for serum CA72-4 in the diagnosis of colorectal cancer](med-13-164-g008){#j_med-2018-0026_fig_008}

3.9. Publication bias analysis {#j_med-2018-0026_s_003_s_009}
------------------------------

There was no publication bias of serum CA72-4 in the diagnosis of colorectal cancer assessed by Deeks'funnel plot ([Figure 9](#j_med-2018-0026_fig_009){ref-type="fig"}) and Egger's line regression test(p=0.49).

![Deeks'funnel plot for evaluation of the publication bias](med-13-164-g009){#j_med-2018-0026_fig_009}

4. Discussion {#j_med-2018-0026_s_004}
=============

Colorectal cancer remains one of the most diagnosed malignant carcinomas that represents a global health problem \[[@j_med-2018-0026_ref_028]\]. It has previously been indicated that delayed diagnosis is the main reason for a poor prognosis, Over the past few decades, investigations have focused on the serum tumor markers for screening or early diagnosis of colorectal cancer. The most clinically used serum biomarkers for colorectal cancer screening or diagnosis in high risk population were CEA, CA199, CA125 CA72-4 and et al \[[@j_med-2018-0026_ref_029], [@j_med-2018-0026_ref_030]\].

Carbohydrate antigen 724(CA72-4), a specific glycoprotein antigen of the tumor associated glycoprotein (TAG-72), is initially used as serum biomarker for pancreatic cancer diagnosis. And recently, it was found that the serum CA72-4 level was elevated in patients with gastric cancer, ovarian cancer and colorectal cancer. Several studies \[[@j_med-2018-0026_ref_016],[@j_med-2018-0026_ref_017],[@j_med-2018-0026_ref_018]\] have evaluated its diagnostic performance as serum biomarkers for colorectal cancer. He *et al* \[8\] evaluated the serum levels of CA72-4 in diagnoses of colorectal cancer. They found that the serum concentration of CA72-4 was significantly higher in colorectal cancer patients compared to healthy controls. The serum level of CA72-4 was also positively correlated with the Duke's stage. Peidong S evaluated the diagnostic performance of serum CA72-4 as a biomarker for colorectal cancer diagnosis \[[@j_med-2018-0026_ref_022]\]. However, they found the diagnostic sensitivity of serum CA72-4 asunsuitable for colorectal cancer screening or diagnosis.

In our meta-analysis, we included 22 publications relevant to serum CA72-4 as a biomarker for colorectal cancer diagnosis and pooled the diagnostic sensitivity, specificity and hierarchical summary receiver operating characteristic curve (HSROC). The combined results demonstrated the diagnostic sensitivity and specificity as 0.50 (95%CI:0.48-0.52) and 0.86 (95%CI:0.84-0.88) respectively for serum CA72-4 as a biomarker in the diagnosis of colorectal cancer. The pooled area under the ROC curve (AUC) was 0.73. The diagnostic performance was especially poor for sensitivity which shows serum CA72-4 is unsuitable as a biomarker for colorectal cancer screening. The low sensitivity for diagnosis of colorectal cancer always leads to high false negative which usually causes a high rate of missed diagnosis.

Several limitations were found in our present meta-analysis: (1) The general methodological quality of the included 22 studies was poor; (2) Significant heterogeneity was found across the 22 publications; (3) Only English and Chinese publications were searched and included in this meta-analysis.
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